ONEMEDNET CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ONEMEDNET CORPORATION (ONMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 300.35 million shares for the 12-month period ending 2023-12-31, per its 10-K/A filed 2024-11-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2024-11-22
- ONEMEDNET CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2023-12-31 was 75.35M shares.
- ONEMEDNET CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 300.35M shares, a 6.01% decline from fiscal 2022.
- ONEMEDNET CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 319.54M shares, a 29685.07% increase from fiscal 2021.
- ONEMEDNET CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 1.07M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | 75.35M shares derived: 10-K/A 12 month − 8-K/A 9 month · filed 2024-11-05 | 300.35M shares 10-K/A · filed 2024-11-05 | |||
| 2023-09-30 | 225.00M shares 8-K/A · filed 2024-11-22 | 168.74K shares 10-Q · filed 2023-11-20 | |||
| 2022-12-31 | 319.54M shares 10-K/A · filed 2024-11-05 | 485.68K shares 10-K · filed 2024-04-09 | |||
| 2021-12-31 | 1.07M shares 10-K · filed 2024-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |